In addition, high CCR2 protein levels were higher in primary lung adenocarcinomas harboring activating mutations in EGFR or KRAS than in EGFR/KRAS wild-type tumors, and this difference was more pronounced when measuring CCR2 selectively in the stromal and CD11b+ myeloid cell areas than within the cancer cell compartments that contain a limited number of infiltrating CCR2-expressing myeloid cells (Fig. 6E). Here, KRAS is linked to lung adenocarcinoma.